Mark Throsby

Chief Scientific Officer • Gadeta

Dr. Mark Throsby has spent more than 20 years in biotech. He gained a PhD in Immunology from Monash University Melbourne, Australia and spent four years as a research fellow with CNRS in Paris. Dr Throsby started his industry career at the formation of Crucell NV and worked for 8 years there in various roles finally as Director of Antibody discovery. He joined Merus NV in 2008 as CSO supporting the development of its bispecific antibody platform and leading preclinical research at the company until 2020. He joined Gadeta BV in 2020, a cell therapy company leveraging the unique targeting properties of the gamma delta TCR, and is currently serving as COO/CSO. He sits on the board of ONA Therapeutics Srl and is Executive Chairman of Alethiomics Ltd

Also speaking

Hemant Dhamne

Head of Process Development – Gene Therapy Vector Facility • King’s College London

Rodolphe Clerval

CEO • Coave Therapeutics

Friedemann Übele

Head of Process Science • Tigen Pharma

Event Info


2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.